...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Revista de la Sociedad Espanola de Enfermeria Nefrologica >Nursing action related to patients on peritoneal dialysis and treatment with Cinacalcet.
【24h】

Nursing action related to patients on peritoneal dialysis and treatment with Cinacalcet.

机译：与患者有关的腹膜透析和西那卡塞治疗的护理作用。

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

ORTIGOSA BARRIOLA, Almudena; SESMERO RAMOS, Carolina; VELAYOS GONZALEZ, Ma Pilar and PORTOLES PEREZ, José. Nursing action related to patients on peritoneal dialysis and treatment with Cinacalcet. Rev Soc Esp Enferm Nefrol [online]. 2007, vol.10, n.3, pp.13-17. ISSN 1139-1375.Secondary hyperparathyroidism in TCRI is a frequent complication and is associated to a high morbidity index in patients on dialysis programmes. Once it has been established, attempts should be made to slow down its development, maintaining adequate bone mineralization and protecting from vascular calcification. This last effect increases the cardiovascular risk, and the risk of amputations and even death. For this reason, there are diet recommendations and several pharmacological treatments. In 2004, Cinacalcet (Mimpara?) appeared, which belongs to the group of calcimimetics, and was approved in Spain in 2005. In order to determine its effectiveness, five patients on peritoneal dialysis and with hyperparathyroidism were monitored, who had not responded to conservative treatment and commenced treatment with Mimpara? in order to determine its effectiveness. A protocol has been designed for nursing attention that lets all the activities be monitored. The analytical results improved notably in all cases. The symptoms referred by patients prior to treatment disappeared after commencing treatment and no adverse side effects were noted. It is important to note that this is a short-term study with a small sample, and therefore it would be interesting to continue working on it. Close control by nursing staff favours adherence to the treatment and the diet, which reflects satisfaction in the patients in question.
机译：ORTIGOSA BARRIOLA，阿尔穆德纳;卡罗莱纳州SESMERO RAMOS; VELAYOS GONZALEZ（马皮拉尔）和PORTOLES PEREZ（何塞）。与患者有关的腹膜透析和西那卡塞治疗的护理作用。 Rev Soc Esp Enferm Nefrol [在线]。 2007，vol.10，n.3，pp.13-17。 ISSN 1139-1375.TCRI中的继发性甲状旁腺功能亢进是一种常见的并发症，并且与接受透析程序的患者的高发病率指数有关。一旦建立，就应尝试减慢其发展，保持足够的骨矿化并防止血管钙化。最后一种作用会增加心血管疾病的风险，并增加截肢甚至死亡的风险。因此，有饮食建议和几种药理学治疗方法。 2004年出现了Cinacalcet（Mimpara？），属于拟钙剂，并于2005年在西班牙获得批准。为了确定其有效性，监测了5例腹膜透析和甲状旁腺功能亢进的患者，他们对保守疗法没有反应治疗并开始使用Mimpara进行治疗？为了确定其有效性。设计了一种用于护理的协议，可以监控所有活动。在所有情况下，分析结果均得到显着改善。在开始治疗后，患者在治疗前转诊的症状消失，并且未观察到不良副作用。重要的是要注意，这是一个短期研究，样本量很小，因此继续进行研究很有趣。护理人员的严格控制有利于坚持治疗和饮食，这反映出患者的满意度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号